NEW YORK--(BUSINESS WIRE)--Carlin Consumer Health (“Carlin”), a preeminent consumer health business that specializes in acquiring leading over the counter (“OTC”) brands, today announced that it has acquired Infirst USA Holdings, LLC (“Infirst”), the parent company of Infirst Healthcare Inc.
Infirst is the marketer of two iconic digestive health brands, Mylanta® and Mylicon®, pursuant to a trademark licensing agreement with McNeil Consumer Pharmaceuticals Co. As part of the transaction, Infirst will now become a wholly owned subsidiary of Carlin Consumer Health.
“We are very excited to be associated with these two great brands,” said Scott Chapman, President and Chief Executive Officer of Carlin. “We believe that Carlin can make important contributions to the continued impressive growth of Infirst, and we look forward to furthering its mission of providing unsurpassed relief for consumer digestive health needs.”
“Carlin, and its impressive healthcare partners, will help Infirst achieve its business goals more quickly and allow us to more rapidly commercialize our innovation pipeline,” said Jamie Barickman, President and CEO of Infirst. “We are very excited about this new phase in the company’s history.”
Founded in 2022, Carlin Consumer Health is sponsored by Hildred Capital Management, Bourne Partners Strategic Capital, and The Emerson Group—and currently markets the OTC acid reducer brand, Zegerid OTC®.
The financial terms of the transaction were not disclosed. Sidley Austin LLP served as legal advisor to Carlin and Wilson Sonsini Goodrich Rosati acted as legal advisor to Infirst. Stifel acted as exclusive financial advisor to Infirst.
Founded in 2013 and based in Westport, CT, Infirst is a long-standing and valued supplier to over 70 top tier retailers in the U.S. A mid-size company, Infirst serves retail and professional channels with a combination direct and broker selling organization, and ships to customers from its warehouse and logistics facility in Plainfield, IN. For more information, please visit infirst-usa.com.
Founded in 2022 and based in New York City, NY, Carlin is a consumer health business uniquely positioned to acquire leading over-the-counter brands. Carlin was formed by leading sponsors, Hildred Capital Management, Bourne Partners Strategic Capital, and The Emerson Group, and initially acquired a leading acid reducer brand, Zegerid OTC®. For more information, please visit carlinconsumerhealth.com/.
Prosek Partners (on behalf of Carlin Consumer Health)